Accelerate Diagnostics (NASDAQ:AXDX) Earns Daily Media Sentiment Rating of 0.00
Headlines about Accelerate Diagnostics (NASDAQ:AXDX) have been trending somewhat negative recently, Accern reports. Accern ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Accelerate Diagnostics earned a news impact score of 0.00 on Accern’s scale. Accern also gave press coverage about the medical research company an impact score of 47.069012195586 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the news stories that may have effected Accern’s rankings:
- Accelerate Diagnostics’ (AXDX) CEO Lawrence Mehren on Q2 2017 Results – Earnings Call Transcript – Seeking Alpha (seekingalpha.com)
- Priming the Pump: What Are Analysts Saying About Accelerate Diagnostics, Inc. (NASDAQ:AXDX)? – Evergreen Caller (evergreencaller.com)
- Accelerate Diagnostics Inc (AXDX) Sees Technical Signals Building … – FLBC News (flbcnews.com)
- Value Composite Update on Accelerate Diagnostics, Inc. (NasdaqCM:AXDX) and SPX FLOW, Inc. (NYSE:FLOW) – Evergreen Caller (evergreencaller.com)
- Accelerate Diagnostics (AXDX) versus Zeltiq Aesthetics (ZLTQ) Head-To-Head Review (americanbankingnews.com)
Shares of Accelerate Diagnostics (NASDAQ:AXDX) opened at 25.15 on Monday. The company’s market capitalization is $1.31 billion. The firm has a 50-day moving average price of $27.87 and a 200-day moving average price of $25.63. Accelerate Diagnostics has a one year low of $19.20 and a one year high of $30.45.
Accelerate Diagnostics (NASDAQ:AXDX) last released its quarterly earnings results on Thursday, August 3rd. The medical research company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by $0.01. The business had revenue of $0.70 million for the quarter, compared to the consensus estimate of $1.40 million. Accelerate Diagnostics had a negative net margin of 5,062.48% and a negative return on equity of 80.75%. Equities analysts forecast that Accelerate Diagnostics will post ($1.18) earnings per share for the current year.
A number of equities research analysts have weighed in on AXDX shares. BidaskClub upgraded Accelerate Diagnostics from a “hold” rating to a “buy” rating in a report on Friday, June 23rd. Zacks Investment Research downgraded Accelerate Diagnostics from a “buy” rating to a “hold” rating in a report on Tuesday, July 4th. BTIG Research reiterated a “buy” rating and issued a $34.00 target price on shares of Accelerate Diagnostics in a report on Wednesday, July 12th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and issued a $32.00 target price (up from $30.00) on shares of Accelerate Diagnostics in a report on Monday, June 5th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Accelerate Diagnostics has a consensus rating of “Buy” and an average price target of $31.00.
In other Accelerate Diagnostics news, insider Steven Reichling sold 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 21st. The stock was sold at an average price of $28.90, for a total transaction of $867,000.00. Following the completion of the transaction, the insider now owns 30,700 shares of the company’s stock, valued at approximately $887,230. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 51.40% of the company’s stock.
Accelerate Diagnostics Company Profile
Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.
Receive News & Ratings for Accelerate Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.